CUAMC
AKBA icon

China Universal Asset Management Company’s Akebia Therapeutics AKBA Stock Holding History

China Universal Asset Management Company’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,721
Closed -$1K – 395
2022
Q3 		$1K Buy
+1,721
New +$675 ﹤0.01% 379

Other funds holding AKBA

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCM
Ovata Capital Management Hong Kong $715M AUM 19.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

China Universal Asset Management Company's AKBA Position: Q4 2022 in Review

China Universal Asset Management Company sold out of Akebia Therapeutics (AKBA) in Q4 2022, closing a stake of 1,721 shares — an estimated $1K sold.

China Universal Asset Management Company first reported a position in AKBA in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 75 funds tracked by Wall St. Rank hold AKBA as of Q4 2022.

  • China Universal Asset Management Company reported no remaining Akebia Therapeutics position as of Q4 2022 after selling out during the quarter.
  • China Universal Asset Management Company sold 1,721 Akebia Therapeutics shares in Q4 2022, an estimated $1K.
  • China Universal Asset Management Company first reported a position in Akebia Therapeutics in Q3 2022 and held it in 1 quarter.
  • China Universal Asset Management Company's Akebia Therapeutics position peaked at $1K in Q3 2022.
  • 75 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2022.

Based on China Universal Asset Management Company's 13F filing for Q4 2022, filed 31 Jan 2023.